Teijin Pharma Limited has applied for manufacturing and marketing approval in Japan for lonapegsomatropin, a once-weekly treatment for pediatric growth hormone deficiency (GHD). The application, submitted to the Pharmaceuticals and Medical Devices Agency on February 12, 2026, is based on global Phase III clinical trial results conducted by Ascendis Pharma. Lonapegsomatropin, developed as TransCon hGH by Ascendis Pharma, delivers unmodified somatropin and has demonstrated superiority in annualized height velocity compared to daily somatropin, with a similar safety profile. Teijin Pharma Limited holds exclusive rights to the treatment in Japan through a licensing agreement with Ascendis Pharma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teijin Limited published the original content used to generate this news brief on February 12, 2026, and is solely responsible for the information contained therein.